MONMOUTH JUNCTION, N.J., & AUCKLAND, New Zealand--(BUSINESS WIRE)-- MicroDose Therapeutx, Inc. (MicroDose) and Nexus6 today announced that they have entered into a non-exclusive agreement whereby MicroDose will be able to provide its next generation electronic dry powder inhaler (DPI) with Nexus6’s SmartinhalerLive™ technology built in. This agreement follows the joint product development program the two companies announced and successfully completed in 2009.
As a result of this latest agreement, MicroDose’s inhaler is able to wirelessly upload dosing and compliance information from the inhaler to a web-based server for data management and reporting. The data collection and global roaming wireless capability of SmartinhalerLiveTM complements MicroDose’s electronic inhaler features thus facilitating better communication between the physician, patient and pharmaceutical company to improve all aspects of care.
The combined system will have benefits in both the clinical trials setting and with in-market products. By improving compliance through reminder features, and through real-time tracking of compliance, patient safety and clinical trial data management are improved. Improved control and monitoring of compliance can significantly reduce the number of patients enrolled in Phase II or Phase III clinical studies. In marketed products, the system represents a move to more personalized care, giving a better understanding of drug usage and patient response to therapy, and improved compliance and adherence.
Michael J. Martin, MicroDose’s VP of Business Development and Licensing indicated that “the combination of Nexus6 Technology and MicroDose’s dry powder inhaler will insure a continuous flow of “real time” clinical information which will benefit physicians, patients and pharmaceutical companies.“
David Evans, CEO of Nexus6 said “this partnership between Nexus6 and MicroDose will enable the drug delivery marketplace to access leading edge data collection and transmission capabilities, thereby increasing pharmaceutical adherence, improving patient well-being and reducing overall health care costs”.
About the MicroDose DPI
The MicroDose DPI is among a number of key proprietary drug delivery platforms developed by MicroDose. By employing piezo electronics, the MicroDose DPI has the potential to deliver enhanced performance versus other inhalers, for efficient and reproducible delivery independent of patient coordination, inhalation rate and posture. MicroDose believes that the flexibility of the inhaler makes it a true platform technology, able to support a broad pipeline of products across the spectrum of patient populations and therapeutic categories.
About MicroDose Therapeutx
MicroDose Therapeutx is a privately-held pharmaceutical company dedicated to improving the quality of life for people suffering from serious diseases. The company focuses on developing proprietary products that address large unmet market opportunities, and on drug delivery platforms for the pulmonary, oral, and transdermal delivery of medications. The company develops its products and technologies independently, as well as in partnership with leading pharmaceutical companies. MicroDose’s products and platforms currently target respiratory disease states such as asthma, chronic obstructive pulmonary disease (COPD), and respiratory syncytial virus (RSV), as well as IBS-C and constipation. More can be found at our website; www.mdtx.com.
Nexus6 Limited is a privately held developer and manufacturer of solutions to increase patient adherence to respiratory medications, leading to improved disease management and reduced healthcare costs.
Nexus6 SmartinhalerLive™ devices monitor and report patients’ medication usage to their healthcare partners, and are used in pharmaceutical clinical trials and respiratory disease management applications for chronic obstructive pulmonary disease, asthma and cystic fibrosis.
SmartinhalerLive™ uses wireless communications technology to provide real time data collection and reporting from drug delivery devices, and builds upon technology used in Nexus6’s SmartTrack® which received 510k clearance to market from the US FDA in October 2009. More information can be found at the Nexus6 website; www.smartinhaler.com
For MicroDose Therapeutx:
Scott Fleming, 732-355-2114
Sr. Vice President, Sales & Marketing
Garth Sutherland, 937-274 2111 ext 104
Chief Operating Officer
KEYWORDS: United States North America Australia/Oceania New Zealand New Jersey
INDUSTRY KEYWORDS: Health Biotechnology Medical Devices Pharmaceutical